Vericel Corporation
Rank #129Op. LeverageVCEL · Nasdaq · Healthcare
Vericel Corporation (VCEL) — Rank #129 by gross profitability (GP/assets 0.41) · ROE 4.5% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0000887359 · all metrics point-in-time as of the filing date.
About
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.
Show moreShow less
The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014.
The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- State
- MI
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- vcel.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-26 | 2024-12-31filed 2025-02-27 | 2023-12-31filed 2024-02-29 | 2022-12-31filed 2023-02-23 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 11.5 | 5.5 | 4.6 | 4.0 |
| Stock-based compensation | 38.8 | 36.5 | 32.3 | 37.2 |
| Change in inventory | 1.2 | 4.3 | (2.9) | 2.6 |
| Change in payables | 3.0 | (0.3) | 3.0 | 1.4 |
| Operating cash flow | 51.9 | 58.2 | 35.3 | 17.7 |
| Investing | ||||
| Capital expenditures | 27.2 | 64.0 | 20.0 | 7.6 |
| Acquisitions, net of cash | — | — | — | — |
| Investing cash flow | (43.9) | (79.0) | (3.1) | (36.2) |
| Financing | ||||
| Debt repaid | — | — | — | — |
| Financing cash flow | 7.1 | 19.1 | 3.6 | 1.0 |
| Summary | ||||
| Free cash flow | 24.7 | (5.8) | 15.3 | 10.1 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?